Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.58 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | MYLK | Q15746 | 1/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666752 | 0.83 | CYP1A2 (0.64) | ACHEALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4859059 | 0.81 | CYP1A2 (0.64) | APPALDH1A1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL11306777 | 0.78 | HTR7 (0.51) | HTR7ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL4647318 | 0.78 | HRH4 (0.48) | ALDH1A1GBA1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4372794 | 0.77 | MYLK (0.60) | ACHEHTR7MYLKCCNCCDK8 | |
| SCHEMBL8492272 | 0.77 | APP (0.54) | ACHEHTR7APPCCNCCDK8 | |
| SCHEMBL31240809 | 0.77 | CCNC (0.58) | ACHEHTR7APPMYLKCCNC | |
| SCHEMBL4820080 | 0.77 | CYP1A2 (0.57) | APPALDH1A1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL21003173 | 0.76 | HRH4 (0.47) | ALDH1A1GBA1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3406133 | 0.76 | NUDT1 (0.51) | CDK8ALDH1A1KMT2ACYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-1280781-B1 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008024634-A1 | PYRIMDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
| US-6630469-B2 | Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, cicadian rhythm disorders and hypertension | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-07 | — | — | US | disclosed |
| EP-1280781-A4 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-1280781-A1 | 5-HT 7 RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1206265-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1206265-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-05-22 | — | — | EP | disclosed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | disclosed |
| WO-2001085701-A1 | 5-HT7 RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001000213-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0001981-B1 | 9-(OMEGA-HETEROARYLAMINO-ALKYLAMINO)-ERYTHROMYCINS, THEIR SALTS, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1981-04-01 | — | — | EP | disclosed |
| US-4256738-A | BACTERICIDES, PYRIMIDINYL, QUINAZOLINYL | BOEHRINGER INGELHEIM GMBH (DE) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032199-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | ACHE 3720/4885HTR7 1/4885APP 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.